Drug Trial Radar · NCT02684032
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Jun 14, 2016
Primary completion
Jan 19, 2022
Study completion Jan 19, 2022
Sponsor
- Lead sponsor
- Celcuity IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and gedatolisib plus palbociclib/letrozole and expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus palbociclib/letrozole or palbociclib/fulvestrant.
Conditions
- Breast Cancer
Interventions
GedatolisibDrug
Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
PalbociclibDrug
Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
LetrozoleDrug
Letrozole at 2.5 mg daily
FulvestrantDrug
Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicitiesTime frame: up to 28 days
- Objective response rate observed in patients in the dose expansion portionTime frame: 16 weeks
- Objective response rate observed in patients in the dose expansion portionTime frame: 16 weeks
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.
Corona, California
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.
Fountain Valley, California
Keck Hospital of USC - Norris Healthcare Center (HC3)
Los Angeles, California
Keck Hospital of USC
Los Angeles, California
LAC+USC Medical Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.
Riverside, California
UCSF - Helen Diller Family Comprehensive Cancer Center
San Francisco, California
UCSF - Helen Diller Family Comprehensive Cancer Center
San Francisco, California
University of Colorado Hospital - Anschutz Inpatient Pavilion (AiP)
Aurora, Colorado
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado
University of Colorado Hospital - Clinical Trials Office (CTO)
Aurora, Colorado
University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)
Aurora, Colorado
Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley Campus
Tampa, Florida
Moffitt Cancer Center
Tampa, Florida
Emory University Hospital Midtown
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
The Emory Clinic
Atlanta, Georgia
Winship Cancer Institute
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Karmanos Cancer Institute
Farmington Hills, Michigan
UNC Cancer Hospital Infusion Pharmacy
Chapel Hill, North Carolina
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
The Ohio State University Wexner Medical Center James Cancer Hospital
Columbus, Ohio
Stefanie Spielman Comprehensive Breast Cancer
Columbus, Ohio
Thomas Jefferson University - Clinical and Regulatory
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee
Henry-Joyce Cancer Clinic
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
U.T. MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Seattle Cancer Care Alliance (SCCA) Investigational Drug Services
Seattle, Washington
Seattle Cancer Care Alliance
Seattle, Washington
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.